---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-086609"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:20:31.119612+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff

## Summary
- Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.
- Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.
- Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.
- Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.
- AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025.

## SEC filing metadata
- accession: 0001193125-24-086609
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/d780895d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-086609
- JSON: https://secwatch.observer/filing/0001193125-24-086609.json
- Plain text: https://secwatch.observer/filing/0001193125-24-086609.txt

## Key facts
- Restructurings & Charges
  Amylyx Pharmaceuticals, Inc. announced a restructuring with charges of approximately $19 million affecting not specified (approximately 70%).
  - Type: restructuring
  - Charge: approximately $19 million
  - Affected area: not specified
  - Headcount: approximately 70%
  source text: Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million. The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000119312524086609/0001193125-24-086609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.